BioCardia (NASDAQ:BCDA) Director Buys $64,584.00 in Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer acquired 70,200 shares of the stock in a transaction on Monday, June 22nd. The shares were acquired at an average price of $0.92 per share, with a total value of $64,584.00. Following the purchase, the director owned 127,338 shares in the company, valued at $117,150.96. This represents a 122.86% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

BioCardia Stock Up 10.1%

BCDA stock opened at $1.20 on Friday. The stock’s 50 day moving average is $1.02 and its two-hundred day moving average is $1.17. BioCardia, Inc. has a 52-week low of $0.78 and a 52-week high of $2.45. The company has a market capitalization of $13.65 million, a PE ratio of -1.32 and a beta of 0.51.

BioCardia (NASDAQ:BCDA) last released its earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). As a group, sell-side analysts anticipate that BioCardia, Inc. will post -0.76 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers acquired a new stake in shares of BioCardia during the 2nd quarter valued at approximately $40,000. Geode Capital Management LLC boosted its holdings in BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the period. Finally, DRW Securities LLC acquired a new position in BioCardia in the fourth quarter worth $72,000. Institutional investors and hedge funds own 20.57% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on BCDA. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research note on Tuesday, June 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.